Has Farid Roman, MD received payments from drug or device companies?

Yes. Drug and device makers reported $61,658 in general payments to Farid Roman, MD across 1,035 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Farid Roman, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Farid Roman, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Farid Roman, MD

Endocrinology, Diabetes & Metabolism · Saint Louis, MONPI 1851366355

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $37,289 of the $61,658 with a category attached, or 60.5%. 60 manufacturers reported payments, led by Novo Nordisk at 35.1% of the total. Reporting peaked in 2019 at $32,582 and has fallen 98.2% since, to $585 in 2025. Among endocrinology, diabetes & metabolism clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$61,658in general payments, 2019–2025

Across 1,035 payments — averaging $59.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$22K
AstraZeneca$19K
Boehringer Ingelheim$5K
Lilly USA, LLC$4K
Abbott$3K
Medtronic$2K
plus $7K from 54 others

What the payments were for

Consulting fees$3,3755%
Speaking & faculty fees$37,28960%
Travel & lodging$2,9955%
Food & beverage$17,95329%
Education$460%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	206	$21,655
AstraZeneca(2 entities)	136	$18,936
Boehringer Ingelheim	31	$5,261
Lilly USA, LLC	59	$4,369
Abbott	153	$2,926
Medtronic(3 entities)	36	$1,666
Dexcom, Inc.	56	$820
Insulet Corporation	62	$634
Senseonics, Incorporated	5	$450
Sanofi-aventis U.S. LLC	22	$426
Merck	20	$288
Johnson & Johnson(2 entities)	15	$240
AbbVie	18	$237
Amgen(2 entities)	12	$219
Amarin Pharma, Inc.	14	$205
Corcept Therapeutics	9	$181
Xeris Pharmaceuticals, Inc.	8	$175
Gilead	10	$161
Sunovion Pharmaceuticals Inc.	17	$155
Bayer	8	$139
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	7	$130
Radius Health, Inc.	6	$119
Akcea Therapeutics, Inc.	6	$112
Ascensia Diabetes Care US Inc.	5	$111
Sanofi	6	$105
SK Life Science, Inc.	6	$103
UCB, Inc.	6	$94
Mannkind Corporation	5	$92
BETA Bionics, Inc.	7	$90
Argenx US, Inc.	3	$87
Antares Pharma, Inc.	5	$87
Grifols USA, LLC	4	$72
Takeda Pharmaceuticals U.S.A., Inc.	4	$72
IBSA Pharma Inc.	4	$64
Acadia Pharmaceuticals Inc	3	$62
Biogen	3	$60
Novartis	3	$59
Valeritas, Inc.	2	$58
GE HealthCare	3	$57
Ironwood Pharmaceuticals, Inc	4	$55
Biohaven Pharmaceuticals, Inc.	3	$53
Lundbeck LLC	3	$52
Kyowa Kirin, Inc.	3	$47
Sumitomo Pharma America, Inc.	2	$46
Neurelis, Inc.	2	$43
Intuity Medical Inc	2	$43
BD	3	$40
EMD Serono, Inc.	2	$39
Verity Pharmaceuticals Inc.	1	$32
Tandem Diabetes Care, Inc.	2	$31
Upsher-smith Laboratories LLC	2	$31
Braintree Laboratories, Inc.	2	$30
Intercept Pharmaceuticals, Inc.	2	$28
Teva Pharmaceuticals USA, Inc.	1	$27
Biohaven Pharmaceutical Holding Company Ltd.	1	$25
Eisai Inc.	1	$25
Vanda Pharmaceuticals Inc.	1	$23
Corium, LLC	1	$22
Catalyst Pharmaceuticals, Inc.	1	$21
Supernus Pharmaceuticals, Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$61,658 in reported general payments places this provider in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri →

Medicare billing

Part B allowed, 2024

$73,897

Medicare patients

430

Services billed

2,672

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	594	$867,106
JardianceEmpagliflozin	372	$450,986
FarxigaDapagliflozin Propanediol	411	$400,105
TrulicityDulaglutide	171	$261,293
MounjaroTirzepatide	203	$250,533
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	104	$133,209
JanuviaSitagliptin Phosphate	95	$113,100
Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt	54	$106,140
Tresiba Flextouch U-200Insulin Degludec	62	$71,308
Tresiba Flextouch U-100Insulin Degludec	116	$70,003
Humulin R U-500 KwikpenInsulin Regular, Human	39	$69,956
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog	74	$56,156
Humalog Kwikpen U-100Insulin Lispro	172	$51,974
Fiasp FlextouchInsulin Aspart (Niacinamide)	65	$47,275
Humulin R U-500Insulin Regular, Human	13	$45,887

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog, Xultophy 100-3.6	$21,655	$945,150703 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog	$4,369	$542,223439 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr	$5,261	$509,502427 claims
AstraZenecaFarxiga	$18,936	$400,105411 claims
MerckJanuvia, Janumet	$288	$144,292113 claims
Radius Health, Inc.Tymlos	$119	$32,19612 claims
AmgenProlia	$219	$29,77717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

Other endocrinology, diabetes & metabolism in Saint Louis

Janet McGillSaint Louis$212K
Kathryn DiemerSaint Louis$57K
Julie SilversteinSaint Louis$49K
Michael WhyteSaint Louis$40K
Alexis McKeeSaint Louis$37K
Sandeep DhindsaSaint Louis$36K
Thomas NickolasSaint Louis$35K
K ThampySaint Louis$35K
Garry TobinSaint Louis$30K
Bharathi RajuSaint Louis$24K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →